Targacept (TRGT)

TRGT»Topics» If the combination of TC-1734 (AZD3480) administered together with other drugs that are commonly prescribed for schizophrenia is not considered to be safe, the commercial potential of TC-1734 (AZD3480) would be adversely affected.

If the combination of TC-1734 (AZD3480) administered together with other drugs that are commonly prescribed for schizophrenia is not considered to be safe, the
commercial potential of TC-1734 (AZD3480) would be adversely affected.

A drug that is generally safe when taken alone may not be safe
or may not be as safe when taken together with other drugs. We expect AstraZeneca to conduct a small clinical trial of TC-1734 (AZD3480) administered together with multiple commonly prescribed treatments for schizophrenia in healthy volunteers to
evaluate the interaction of the drugs and the combined effects on metabolism and safety. If the interaction of TC-1734 (AZD3480) and any or all of the commonly prescribed

treatments for schizophrenia adversely affects the metabolism of TC-1734 (AZD3480) such that TC-1734 (AZD3480) and any of
those treatments are determined to be unsafe together, it could limit the commercial potential of TC-1734 (AZD3480) as a treatment for cognitive deficits in schizophrenia. Moreover, AstraZeneca could decide not to advance TC-1734 (AZD3480) as a
treatment for cognitive deficits in schizophrenia, which would limit the overall commercial potential of TC-1734 (AZD3480). Furthermore, if the interaction of TC-1734 (AZD3480) with any of these commonly prescribed treatments adversely affects the
metabolism of TC-1734 (AZD3480), AstraZeneca could decide not to conduct any Phase II clinical trials of TC-1734 (AZD3480) and terminate its agreement with us. If AstraZeneca terminates our agreement, it would delay our development of TC-1734
(AZD3480).

If the combination of TC-1734 (AZD3480) administered together with other drugs that are commonly prescribed for
schizophrenia is not considered to be safe, the commercial potential of TC-1734 (AZD3480) would be adversely affected.

A drug that is
generally safe when taken alone may not be safe or may not be as safe when taken together with other drugs. We expect AstraZeneca to conduct a small clinical trial of TC-1734 (AZD3480) administered together with multiple commonly prescribed
treatments for schizophrenia in healthy volunteers to evaluate the interaction of the drugs and the combined effects on metabolism and safety. If the interaction of TC-1734 (AZD3480) and any or all of the commonly prescribed treatments for
schizophrenia adversely affects the metabolism of TC-1734 (AZD3480) such that TC-1734 (AZD3480) and any of those treatments are determined to be unsafe together, it could limit the commercial potential of TC-1734 (AZD3480) as a treatment for
cognitive deficits in schizophrenia. Moreover, AstraZeneca could decide not to advance TC-1734 (AZD3480) as a treatment for cognitive deficits in schizophrenia, which would limit the overall commercial potential of TC-1734 (AZD3480). Furthermore, if
the interaction of TC-1734 (AZD3480) with any of these commonly prescribed treatments adversely affects the metabolism of TC-1734 (AZD3480), AstraZeneca could decide not to conduct any Phase II clinical trials of TC-1734 (AZD3480) and terminate its
agreement with us. If AstraZeneca terminates our agreement, it would delay our development of TC-1734 (AZD3480).